BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33640709)

  • 1. Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?
    Diamantopoulos PT; Viniou NA
    Leuk Res; 2021 Apr; 103():106543. PubMed ID: 33640709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.
    Diamantopoulos PT; Pappa V; Symeonidis A; Kotsianidis I; Galanopoulos A; Papadaki H; Anagnostopoulos A; Vassilopoulos G; Zikos P; Hatzimichael E; Papaioannou M; Megalakaki A; Kotsopoulou M; Repousis P; Dimou M; Solomou E; Pontikoglou C; Kyriakakis G; Tsokanas D; Papoutselis MK; Papageorgiou S; Kourakli A; Panayiotidis P; Viniou NA
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):114-121. PubMed ID: 31884152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
    Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ;
    Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
    Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
    Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.
    Jung KS; Kim YJ; Kim YK; Park SK; Kim HG; Kim SJ; Park J; Choi CW; Do YR; Kim I; Park S; Mun YC; Jeong SH; Kim MK; Yi HG; Chang MH; Kim SY; Lee JH; Jang JH
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):656-664. PubMed ID: 31375393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
    Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
    Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
    Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Tallman MS; Gore SD;
    Br J Haematol; 2014 Aug; 166(3):352-9. PubMed ID: 24712482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
    Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
    Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
    Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
    Diamantopoulos P; Koumbi D; Kotsianidis I; Pappa V; Symeonidis A; Galanopoulos A; Zikos P; Papadaki HA; Panayiotidis P; Dimou M; Hatzimichael E; Vassilopoulos G; Delimpasis S; Mparmparousi D; Papageorgiou S; Variami E; Kyrtsonis MC; Megalakaki A; Kotsopoulou M; Repousis P; Adamopoulos I; Kontopidou F; Christoulas D; Kourakli A; Tsokanas D; Konstantinos Papoutselis M; Kyriakakis G; Viniou NA;
    Cancer Med; 2019 May; 8(5):2056-2063. PubMed ID: 30897290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
    Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
    Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies.
    Wan Z; Han B
    Aging (Albany NY); 2021 Mar; 13(8):11120-11134. PubMed ID: 33818418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients.
    Spetsieris N; Diamantopoulos P; Zervakis K; Giannakopoulou N; Rougala N; Garefalakis G; Skarlatou V; Viniou NA
    Medicine (Baltimore); 2018 Apr; 97(17):e0505. PubMed ID: 29703015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
    Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
    Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
    Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
    Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.